Investigating how BET proteins can be targeted for cancer treatment
Official title: Targeting the ET domain of BET proteins: specificity and selectivity
Funded at University of Florida · NIH-11045017 · Data updated 2026-11-12
This study is exploring how to create safer and more effective cancer treatments by focusing on certain proteins that are involved in cancer and viral infections, aiming to find new drugs that can target these proteins without causing as much harm to patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Florida NIH-funded |
| Lab location | 1 site (Gainesville, United States) |
| Project start | June 1, 2023 |
| Project end | March 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $284,920 |
| NIH project number | 5R01GM149646-03 |
| Project ID | NIH-11045017 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with cancers that involve BET proteins, particularly those who have not responded well to existing treatments.
✕Less likely to help
Patients with cancers unrelated to BET proteins or those who are not eligible for targeted therapies may not benefit from this research.
What this research studies
This research focuses on BET proteins, which play a significant role in various cancers and viral infections. The project aims to understand the ET domain of these proteins, which has the potential to selectively bind to specific BET proteins, reducing toxicity associated with current treatments. By utilizing advanced computational tools and machine learning, the researchers will identify and characterize potential drug candidates that can specifically inhibit these proteins. This approach seeks to enhance the specificity of cancer therapies, making them safer and more effective for patients.
Why it matters
Potential benefit: If successful, this research could lead to the development of targeted therapies that minimize side effects for cancer patients.
How similar studies have gone: Previous research has shown promise in targeting BET proteins for cancer treatment, indicating that this approach could be a meaningful advancement in the field.
Where this research is happening
-
University of Florida
Gainesville, United States Active
Researchers
- Principal investigator: Perez, Alberto — University of Florida
- Study coordinator: Perez, Alberto
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.